GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (MEX:RARE) » Definitions » Shiller PE Ratio

Ultragenyx Pharmaceutical (MEX:RARE) Shiller PE Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ultragenyx Pharmaceutical Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ultragenyx Pharmaceutical Shiller PE Ratio Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Shiller PE Ratio Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ultragenyx Pharmaceutical's Shiller PE Ratio

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Shiller PE Ratio falls into.



Ultragenyx Pharmaceutical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ultragenyx Pharmaceutical's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Ultragenyx Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-33.69/131.7762*131.7762
=-33.690

Current CPI (Mar. 2024) = 131.7762.

Ultragenyx Pharmaceutical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -5.836 100.560 -7.648
201409 -6.713 100.428 -8.808
201412 -7.670 99.070 -10.202
201503 -9.604 99.621 -12.704
201506 -13.023 100.684 -17.045
201509 -17.405 100.392 -22.846
201512 -24.933 99.792 -32.924
201603 -23.239 100.470 -30.480
201606 -27.001 101.688 -34.990
201609 -31.710 101.861 -41.023
201612 -36.080 101.863 -46.675
201703 -30.691 102.862 -39.318
201706 -31.091 103.349 -39.643
201709 -33.937 104.136 -42.945
201712 -37.119 104.011 -47.028
201803 11.264 105.290 14.098
201806 -20.828 106.317 -25.816
201809 -32.547 106.507 -40.269
201812 -33.969 105.998 -42.230
201903 -35.304 107.251 -43.377
201906 -33.039 108.070 -40.287
201909 -38.694 108.329 -47.069
201912 -30.553 108.420 -37.135
202003 -48.068 108.902 -58.165
202006 9.464 108.767 11.466
202009 -24.963 109.815 -29.955
202012 -7.360 109.897 -8.825
202103 -41.495 111.754 -48.929
202106 -36.030 114.631 -41.419
202109 -22.207 115.734 -25.285
202112 -36.720 117.630 -41.136
202203 -43.605 121.301 -47.371
202206 -45.467 125.017 -47.925
202209 -70.402 125.227 -74.084
202212 -42.111 125.222 -44.315
202303 -41.998 127.348 -43.458
202306 -38.574 128.729 -39.487
202309 -38.844 129.860 -39.417
202312 -25.801 129.419 -26.271
202403 -33.690 131.776 -33.690

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ultragenyx Pharmaceutical  (MEX:RARE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ultragenyx Pharmaceutical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (MEX:RARE) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (MEX:RARE) Headlines